Independent Medical Education Grant Request for Proposals: Guideline Concordant Care and Emerging Data for Patients with Muscle Invasive Bladder Cancer (MIBC) through locally advanced or metastatic Urothelial Carcinoma (la/mUC)
Supports educational projects that enhance healthcare professionals' knowledge and use of current guidelines for advanced bladder cancer and urothelial carcinoma care.
Funder: Pfizer Inc.
Due Dates: July 2, 2026 (Submission deadline — full application, 23:59 EST)
Funding Amounts: Individual projects: $10,000–$230,000; max duration 18–24 months; total program budget $500,000.
Summary: Supports educational initiatives to advance healthcare professionals’ knowledge and implementation of guideline-concordant, multidisciplinary care for advanced bladder cancer and urothelial carcinoma.
Description
This grant program is designed to fund independent medical education projects that address gaps in awareness, knowledge, and application of current and emerging data for muscle invasive bladder cancer (MIBC) and locally advanced or metastatic urothelial carcinoma (la/mUC). The focus is on guideline-concordant care, holistic management, multidisciplinary collaboration, and shared decision-making to optimize patient outcomes. Supported projects may include live or virtual educational sessions, curriculum-based learning, workshops, and other innovative educational formats targeting healthcare professionals involved in the treatment of advanced bladder cancer.
